Press release
Mar 22, 2016

Sosei appoints Peter Bains as COO and CEO-elect


Tokyo, Japan March 22 2016: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) today announces the appointment of Mr Peter Bains as Representative Executive Officer and Chief Operating Officer (COO) effective from April 1 2016. Mr Bains will assume responsibility for all operational activities of Sosei and will report to Mr Shinichi Tamura in his ongoing capacity as Group Chairman, President and Chief Executive Officer (CEO). Further, it is expected that Mr Bains will become Representative Executive Officer, President and Chief Executive Officer (CEO) upon approval by the Board of Directors following Sosei Group’s Annual General Meeting in June 2016. At the same time, Mr Shinichi Tamura, Sosei founder and Group Chairman, President and CEO, is expected to become Representative Executive Officer and Executive Chairman.

1. The reason for appointment

    To further strengthen/develop the system of management to improve our corporate value and reinforce the management base

2. The name and title of new Representative Executive Officer

     Name: Peter Bains

     Title: Representative Executive Officer and Chief Operating Officer (COO)

3. Brief summary of Peter Bains

4. Effective date

    As of April 1 2016

    Peter Bains, born on September 26 1957, has nearly 30 years of experience in the pharmaceutical industry encompassing strategic and operational leadership expertise across       global geographies, functions and business segments. He had a 23-year career at GlaxoSmithKline, where he held multiple senior roles including General Manager of China, VP     of International Business Development, Head of Global Marketing and Senior VP of International Commercial Development. From 2009, he has been a consultant specialising in       supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies. He currently serves as an Non-executive Director at Sosei Group       Corporation, and as CEO at Syngene, a subsidiary of Biocon, Asia’s leading biotechnology company.

    Commenting on the appointment, Mr Shinichi Tamura said: “I am delighted to announce Mr Bains as my successor in leading Sosei Group into its next phase of evolution and           growth. Mr Bains has served Sosei for the past five years in his capacity as a Nonexecutive Director and in this role has worked closely with me and the Board to shape Sosei’s       evolving strategy to become a global biopharmaceutical business. Along with his deep insight of our Group and its activities, Mr Bains brings a strong track record of successful         leadership and operational experience in the biopharmaceutical sector that will serve to strengthen our company's leadership and capabilities in the dynamic and exciting future       we are planning.”

    Mr Bains added: “I am both personally honoured and also extremely excited at the prospect of taking up these new roles and I would like to thank Mr Tamura and the Sosei               Board for their trust and support. Sosei Group is now at a very dynamic point in its history as it seeks to expand its operational scope and scale, and I am looking forward to               contributing to its rapid evolution into a truly global biopharmaceutical company.” 

 


 DOWNLOAD PDF